Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy.
Bucci C, von Delft A, Christian A, Flemming VM, Harrison A, Halliday J, Collier J, Manganis C, Klenerman P, Irving W, Barnes E. Bucci C, et al. J Gen Virol. 2013 Jun;94(Pt 6):1259-1265. doi: 10.1099/vir.0.051052-0. Epub 2013 Mar 13. J Gen Virol. 2013. PMID: 23486666
Predictors of hepatitis C treatment response: what's new?
Berry L, Irving W. Berry L, et al. Expert Rev Anti Infect Ther. 2014 Feb;12(2):183-91. doi: 10.1586/14787210.2014.874283. Epub 2014 Jan 3. Expert Rev Anti Infect Ther. 2014. PMID: 24404996 Review.
The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
Backx M, Lewszuk A, White JR, Cole J, Sreedharan A, van Sanden S, Diels J, Lawson A, Neal KR, Wiselka MJ, Ito T, Irving WL. Backx M, et al. Among authors: irving wl. J Viral Hepat. 2014 Mar;21(3):208-15. doi: 10.1111/jvh.12132. Epub 2013 Aug 1. J Viral Hepat. 2014. PMID: 24438682
MAIT cells are activated during human viral infections.
van Wilgenburg B, Scherwitzl I, Hutchinson EC, Leng T, Kurioka A, Kulicke C, de Lara C, Cole S, Vasanawathana S, Limpitikul W, Malasit P, Young D, Denney L; STOP-HCV consortium; Moore MD, Fabris P, Giordani MT, Oo YH, Laidlaw SM, Dustin LB, Ho LP, Thompson FM, Ramamurthy N, Mongkolsapaya J, Willberg CB, Screaton GR, Klenerman P. van Wilgenburg B, et al. Nat Commun. 2016 Jun 23;7:11653. doi: 10.1038/ncomms11653. Nat Commun. 2016. PMID: 27337592 Free PMC article.
Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank.
McLauchlan J, Innes H, Dillon JF, Foster G, Holtham E, McDonald S, Wilkes B, Hutchinson SJ, Irving WL; HCV Research UK Steering Committee. McLauchlan J, et al. Among authors: irving wl. Int J Epidemiol. 2017 Oct 1;46(5):1391-1391h. doi: 10.1093/ije/dyw362. Int J Epidemiol. 2017. PMID: 28338838 Free PMC article. No abstract available.
Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus.
Ansari MA, Pedergnana V, L C Ip C, Magri A, Von Delft A, Bonsall D, Chaturvedi N, Bartha I, Smith D, Nicholson G, McVean G, Trebes A, Piazza P, Fellay J, Cooke G, Foster GR; STOP-HCV Consortium; Hudson E, McLauchlan J, Simmonds P, Bowden R, Klenerman P, Barnes E, Spencer CCA. Ansari MA, et al. Nat Genet. 2017 May;49(5):666-673. doi: 10.1038/ng.3835. Epub 2017 Apr 10. Nat Genet. 2017. PMID: 28394351 Free PMC article.
Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries.
da Silva Filipe A, Sreenu V, Hughes J, Aranday-Cortes E, Irving WL, Foster GR, Agarwal K, Rosenberg W, Macdonald D, Richardson P, Aldersley MA, Wiselka M, Ustianowski A, McLauchlan J, Thomson EC. da Silva Filipe A, et al. Among authors: irving wl. J Hepatol. 2017 Dec;67(6):1348-1350. doi: 10.1016/j.jhep.2017.06.035. Epub 2017 Aug 5. J Hepatol. 2017. PMID: 28789880 No abstract available.
230 results